⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10584179 | 0.92 | — | — | |
| SCHEMBL5487541 | 0.78 | ANPEP (0.55) | — | |
| SCHEMBL6359996 | 0.72 | ANPEP (0.42) | — | |
| SCHEMBL1726025 | 0.70 | ANPEP (0.46) | — | |
| SCHEMBL28514987 | 0.70 | — | — | |
| SCHEMBL14354252 | 0.69 | ANPEP (0.39) | — | |
| SCHEMBL10348835 | 0.69 | MEN1 (0.45) | — | |
| SCHEMBL17287861 | 0.68 | — | — | |
| Butyl Boronic Acid SCHEMBL15975 | 0.67 | — | — | |
| SCHEMBL5575748 | 0.67 | ANPEP (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325992-A1 | MODULATION OF AXON DEGENERATION | GENENTECH INC (US) | 2018-11-15 | — | — | US | disclosed |
| US-9937224-B2 | Modulation of axon degeneration | GENENTECH, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2017202890-A1 | METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING MYELOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-30 | — | — | WO | disclosed |
| US-20160279190-A1 | MODULATION OF AXON DEGENERATION | GENENTECH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160199457-A1 | MODULATION OF AXON DEGENERATION | GENENTECH INC (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160161470-A1 | MODULATION OF AXON DEGENERATION | GENENTECH, INC. | 2016-06-09 | — | — | US | disclosed |
| EP-2919786-A2 | CRYSTALLINE BORTEZOMIB PROCESS | Shilpa Medicare Limited (IN) | 2015-09-23 | — | — | EP | disclosed |
| EP-2827861-A1 | COMPOSITION AND METHODS FOR CELL MODULATION | Aposignal Bioscience LLC (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2014076713-A2 | CRYSTALLINE BORTEZOMIB PROCESS | SHILPA MEDICARE LIMITED (IN) | 2014-05-22 | — | — | WO | disclosed |
| WO-2013142376-A1 | COMPOSITION AND METHODS FOR CELL MODULATION | APOSIGNAL BIOSCIENCE LLC (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20120328609-A1 | Modulation of Axon Degeneration | GENENTECH, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2010124296-A2 | COMPOSITIONS CONTAINING HC•HA COMPLEX AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2010-10-28 | — | — | WO | disclosed |